Skip to main content
Premium Trial:

Request an Annual Quote

European Consortium Nets €1M for Test to Predict Bladder Cancer Immunotherapy Response

NEW YORK – A European research consortium that includes PamGene, Novigenix, and Radboud University Medical Center said on Thursday they received a grant from Eurostars for up to €1 million ($1.1 million) to develop a diagnostic that predicts which bladder cancer patients are likely to respond to immunotherapy.

The three entities have formed a Dutch-Swiss consortium called PRECISE. The group hopes to develop an in vitro liquid biopsy diagnostic that combines two multiomics approaches, mRNA and kinase activity profiling. The test will be codeveloped by Dutch diagnostics company PamGene and Swiss precision medicine company Novigenix. Researchers at the Radboud University Medical Center in the Netherlands will evaluate the test in a prospective clinical study.

PamGene has previously developed two tests that predict immunotherapy response using its expertise in kinase activity profiling: one for melanoma and another for non-small cell lung cancer.

Studies have shown that around 20 percent of cancer patients have an enduring benefit from immunotherapy. "The objective of this collaboration is to fulfill a significant medical unmet need," Niven Mehra, an oncologist at Radboud University Medical Center, said in a statement. "Time is a critical factor in bladder cancer treatment because of the cancer's aggressive nature."

Earlier proof-of-concept studies by the consortium suggested that combining data on host-immune response characteristics using mRNA transcriptomics and protein kinase activity profiling could accurately predict whether metastatic bladder cancer patients were likely to respond to immunotherapy.

In December, the PRECISE consortium received a separate €1 million grant from Eurostars to similarly use mRNA and kinase activity profiling to identify multiomic signatures that can predict which metastatic urothelial cancer patients respond to checkpoint inhibitors.

The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.